Quick Answer
Voyager Therapeutics, Inc. reported R&D Expense of $134.67 million for fiscal year 2025.
Voyager Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $134.67M | +5.7% |
| 2024 | $127.37M | +38.2% |
| 2023 | $92.17M | +51.7% |
| 2022 | $60.76M | -17.6% |
| 2021 | $73.79M | -32.2% |
| 2020 | $108.75M | -9.2% |
| 2019 | $119.73M | +84.5% |
| 2018 | $64.91M | +4.2% |
| 2017 | $62.26M | +47.4% |
| 2016 | $42.25M | +52.6% |
| 2015 | $27.68M | +211.1% |
| 2014 | $8.90M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $35.87M | +18.6% | +14.5% |
| June 30, 2025 | $31.33M | -9.1% | -0.6% |
| March 31, 2025 | $31.53M | +16.4% | +4.2% |
| September 30, 2024 | $30.24M | +16.9% | -12.2% |
| June 30, 2024 | $34.45M | +56.7% | +27.2% |
| March 31, 2024 | $27.09M | +45.9% | +4.8% |
| September 30, 2023 | $25.86M | +33.7% | +17.6% |
| June 30, 2023 | $21.98M | +75.5% | +18.4% |
- Voyager Therapeutics, Inc. showed an increase of +5.7% in R&D Expense compared to the prior fiscal year.
- Over the 2014–2025 period, Voyager Therapeutics, Inc.’s r&d expense has grown by 1413.5% (from $8.90 million to $134.67 million).
- The most recent figure is from Voyager Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 9, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: